Clinical Trials List
Protocol NumberGHPanc-1-001
NCT Number(ClinicalTrials.gov Identfier)NCT03310632
Completed
2018-02-14 - 2022-12-31
Phase I/II
Recruiting2
ICD-10C25
Malignant neoplasm of pancreas
ICD-9157.9
Malignant neoplasm of pancreas, part unspecified
A Phase I/II study to determine the maximum tolerated dose (MTD) and to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of antroquinonol in combination with nab-paclitaxel and gemcitabine in first line metastatic pancreatic cancer.
-
Trial Applicant
COVANCE TAIWAN SERVICES LIMITED
-
Sponsor
Golden Biotechnology Corporation
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Yee Chao Division of Hematology & Oncology
- 李潤平 Division of Radiology
- Yi-Ping Hung Division of Hematology & Oncology
- Ming-Huang Chen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
3 Recruiting
Audit
CRO
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
2 Recruiting
Audit
None
Condition/Disease
Pancreatic Neoplasm
Objectives
The proposed clinical trial is a Phase I/II study designed to evaluate antroquinonol in combination with nab-paclitaxel and gemcitabine in first line treatment naïve subjects with Stage IV metastatic pancreatic carcinoma. The first part of study will focus on the treatment of pancreatic cancer with 200 mg TID and 300 mg TID, clinical treatment duration of 4 weeks, to determine the MTD or MFD (based on PK and capsules strength) of antroquinonol in combination with a standard dose regimen of nab-paclitaxel and gemcitabine. The extended Phase II will focus on the efficacy of antroquinonol with SOC. Safety and pharmacokinetic profiles will be studied in the proposed clinical trial.
Test Drug
Hocena
Active Ingredient
Antroquinonol
Dosage Form
Capsule
Dosage
100
Endpoints
Primary Outcome Measures:
1. MTD.
Secondary Outcome Measures:
1. tumor assessment in millimeters.
2. Body Surface Area in meter^2.
3. Maximum Plasma Concentration.
4. Area Under the Curve.
5. CA19-9 level in units per milli-liter.
6. Eastern Cooperative Oncology Group (ECOG) status.
1. MTD.
Secondary Outcome Measures:
1. tumor assessment in millimeters.
2. Body Surface Area in meter^2.
3. Maximum Plasma Concentration.
4. Area Under the Curve.
5. CA19-9 level in units per milli-liter.
6. Eastern Cooperative Oncology Group (ECOG) status.
Inclution Criteria
1. Male and female patients ≥18 years of age.
2. Histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas, measurable according to the RECIST 1.1.
3. Diagnosed with metastatic disease within 6 weeks before enrollment.
4. Treatment-naïve patients with metastatic pancreatic adenocarcinoma who have received no previous systemic therapy (except adjuvant or neoadjuvant therapy if progression occurred >6 months from last treatment or surgery, respectively, and no prior nab-paclitaxel).
5. Adequate hematologic, hepatic, and renal function, including:
(1) Hemoglobin ≥9 g/dL
(2) Absolute neutrophil count ≥1500/mm3
(3) Platelet count ≥100 000/mm3
(4) Total bilirubin ≤1.25 × upper limit of normal (ULN)
(5) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN; for patients with hepatic metastases, ALT and AST ≤5 × ULN
(6) Albumin ≥3 mg/dL
(7) Serum creatinine ≤1.5 mg/dL or calculated creatinine clearance ≥50 mL/min as determined by the Cockcroft-Gault equation.
6. ECOG performance status of 0 or 1.
7. For women of childbearing potential, a negative serum pregnancy test result at Screening.
8. Willing to use 2 medically accepted and effective methods of contraception from the list below during the study (both men and women as appropriate) and for 3 months after the last dose of study drug:
a. Established use of oral, injected, or implanted hormonal methods of contraception
b. Placement of an intrauterine device or intrauterine system
c. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository
d. Male sterilization (with the appropriate postvasectomy documentation of the absence of sperm in the ejaculate)
e. True abstinence (when this is in line with the preferred and usual lifestyle of the patient).
9. Patient must be able to provide written informed consent for participation in the study.
10. Life expectancy ≥12 weeks as assessed by the Investigator.
2. Histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas, measurable according to the RECIST 1.1.
3. Diagnosed with metastatic disease within 6 weeks before enrollment.
4. Treatment-naïve patients with metastatic pancreatic adenocarcinoma who have received no previous systemic therapy (except adjuvant or neoadjuvant therapy if progression occurred >6 months from last treatment or surgery, respectively, and no prior nab-paclitaxel).
5. Adequate hematologic, hepatic, and renal function, including:
(1) Hemoglobin ≥9 g/dL
(2) Absolute neutrophil count ≥1500/mm3
(3) Platelet count ≥100 000/mm3
(4) Total bilirubin ≤1.25 × upper limit of normal (ULN)
(5) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN; for patients with hepatic metastases, ALT and AST ≤5 × ULN
(6) Albumin ≥3 mg/dL
(7) Serum creatinine ≤1.5 mg/dL or calculated creatinine clearance ≥50 mL/min as determined by the Cockcroft-Gault equation.
6. ECOG performance status of 0 or 1.
7. For women of childbearing potential, a negative serum pregnancy test result at Screening.
8. Willing to use 2 medically accepted and effective methods of contraception from the list below during the study (both men and women as appropriate) and for 3 months after the last dose of study drug:
a. Established use of oral, injected, or implanted hormonal methods of contraception
b. Placement of an intrauterine device or intrauterine system
c. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository
d. Male sterilization (with the appropriate postvasectomy documentation of the absence of sperm in the ejaculate)
e. True abstinence (when this is in line with the preferred and usual lifestyle of the patient).
9. Patient must be able to provide written informed consent for participation in the study.
10. Life expectancy ≥12 weeks as assessed by the Investigator.
Exclusion Criteria
1. Islet-cell neoplasms or locally advanced disease.
2. Chemo-, hormone-, or immunotherapy or investigational drug at Screening or prior to enrollment.
3. Treatment with any drug(s) known to be a strong inhibitor or inducer of CYP2C19,CYP3A4, CYP2C8, and CYP2E1 within 14 days of the date of first administration of study drug and during study treatment.
4. Other malignancies diagnosed within the past 5 years (other than curatively treated cervical cancer in situ, nonmelanoma skin cancer, superficial bladder tumors Ta [noninvasive tumor] and TIS [carcinoma in situ], or nonmetastatic prostate cancer Stage 1 to 2, which has been previously treated with surgery or radiation therapy, and serum prostate-specific antigen is within normal limits [test performed within the past 12 months prior to the date of first administration of study drug]).
5. Patients with any serious active infection (ie, requiring an IV antibiotic, antifungal, or antiviral agent).
6. Patients with known human immunodeficiency virus, active hepatitis B, or active hepatitis C.
7. Patients who have any other life-threatening illness or organ system dysfunction, which in the opinion of the Investigator, would either compromise patient safety or interfere with the evaluation of the safety of the study drug.
8. Known or suspected substance abuse or alcohol abuse.
9. Uncontrolled intercurrent illness, including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs from study treatment, or compromise the ability of the patient to give written informed consent.
10. Inability to swallow oral medications or a recent acute gastrointestinal disorder with diarrhea, (eg, Crohn's disease), malabsorption, or CTCAE Grade >2 diarrhea of any etiology at baseline.
11. Female patients who are pregnant or breastfeeding, or male or female patients of reproductive potential who are not employing an effective method of contraception.
12. Any known hypersensitivity to any component of nab-paclitaxel, gemcitabine, or antroquinonol.
2. Chemo-, hormone-, or immunotherapy or investigational drug at Screening or prior to enrollment.
3. Treatment with any drug(s) known to be a strong inhibitor or inducer of CYP2C19,CYP3A4, CYP2C8, and CYP2E1 within 14 days of the date of first administration of study drug and during study treatment.
4. Other malignancies diagnosed within the past 5 years (other than curatively treated cervical cancer in situ, nonmelanoma skin cancer, superficial bladder tumors Ta [noninvasive tumor] and TIS [carcinoma in situ], or nonmetastatic prostate cancer Stage 1 to 2, which has been previously treated with surgery or radiation therapy, and serum prostate-specific antigen is within normal limits [test performed within the past 12 months prior to the date of first administration of study drug]).
5. Patients with any serious active infection (ie, requiring an IV antibiotic, antifungal, or antiviral agent).
6. Patients with known human immunodeficiency virus, active hepatitis B, or active hepatitis C.
7. Patients who have any other life-threatening illness or organ system dysfunction, which in the opinion of the Investigator, would either compromise patient safety or interfere with the evaluation of the safety of the study drug.
8. Known or suspected substance abuse or alcohol abuse.
9. Uncontrolled intercurrent illness, including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs from study treatment, or compromise the ability of the patient to give written informed consent.
10. Inability to swallow oral medications or a recent acute gastrointestinal disorder with diarrhea, (eg, Crohn's disease), malabsorption, or CTCAE Grade >2 diarrhea of any etiology at baseline.
11. Female patients who are pregnant or breastfeeding, or male or female patients of reproductive potential who are not employing an effective method of contraception.
12. Any known hypersensitivity to any component of nab-paclitaxel, gemcitabine, or antroquinonol.
The Estimated Number of Participants
-
Taiwan
24 participants
-
Global
52 participants
